Therapeutic Options for Early-Stage Uterine Papillary Serous Carcinomas, Carcinosarcomas, and Clear-Cell and Mixed-Cell Histologies
Type II endometrial carcinomas, accounting for 10–20 % of women diagnosed, are typically higher grade, diagnosed at a later stage of the disease, and with precursor lesions rarely identified. Type II endometrial carcinomas include uterine papillary serous carcinoma, carcinosarcoma, and clear-cell, mixed, mucinous, squamous, mesonephric, undifferentiated, and grade III endometrioid type carcinomas. Type II tumors are more aggressive, proposed to develop from endometrial intraepithelial carcinoma, a malignant transformation from atrophic endometrium or benign polyp epithelium, secondary to mutations in p53. Though uterine papillary serous carcinoma (UPSC) accounts for only 10 % of endometrial carcinomas, it accounts for nearly 40 % of endometrial cancer deaths . Although vaginal bleeding is still the most common presenting symptom, it typically manifests in the UPSC patient at a much later stage, and other common presenting complaints include bloating and increased abdominal girth, early satiety, and other symptoms typical to epithelial ovarian cancer presentation.
KeywordsEndometrial Cancer Endometrial Carcinoma Myometrial Invasion Common Present Complaint Malignant Mixed Mullerian Tumor
- 1.Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, editors. SEER cancer statistics review, 1975–2010. Bethesda: National Cancer Institute. http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, 2013.
- 4.Hoffman B, Schorge J, Schaffer J, Halvorson L, Bradshaw K, Cunningham F. Williams gynecology. 2nd ed. New York: McGraw-Hill; 2012.Google Scholar
- 25.Rajshekar SK, Guruprasad B, Shakunthala PN, Rathod P, Devi U, Bafna UD. Malignant mixed Mullerian tumour of the uterus. Cancer. 2013;7:302.Google Scholar
- 31.Reed NS, Mangioni C, Malmström H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group study (protocol 55874). Eur J Cancer. 2008;44:808.CrossRefPubMedGoogle Scholar
- 34.Wolfson AH, Brady MF, Rocereto T, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007;107:177.PubMedCentralCrossRefPubMedGoogle Scholar